Neurocrine Acquires Soleno Therapeutics

Neurocrine Biosciences is acquiring Soleno Therapeutics, enhancing its portfolio with VYKAT™ XR, the first FDA-approved treatment for hyperphagia in Prader-Willi syndrome. This acquisition represents a significant therapeutic advancement and strengthens Neurocrine's position in rare disease and endocrinology markets. The deal underscores the company's strategy to integrate innovative treatments that address critical unmet patient needs. Soleno's lead drug offers a transformative therapy, marking a key expansion for Neurocrine's specialized offerings.